Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1447-0756.1988.tb00101.xDOI Listing

Publication Analysis

Top Keywords

anti-progestin compound
4
compound ru486
4
ru486 gonadotropin
4
gonadotropin release
4
release rat
4
rat anterior
4
anterior pituitary
4
pituitary cells
4
cells vitro
4
anti-progestin
1

Similar Publications

Effects of mifepristone, a model compound with anti-progestogenic activity, on the reproduction of African clawed frog (Xenopus laevis).

J Hazard Mater

December 2024

University of South Bohemia in České Budějovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Research Institute of Fish Culture and Hydrobiology, Zátiší 728/II, 38925 Vodňany, Czech Republic. Electronic address:

This is the first study on how a substance with anti-progestogenic activity affects amphibian reproduction. Mifepristone, a synthetic anti-progestin used in abortion pills, was chosen as model compound. African clawed frog (Xenopus laevis) females were exposed to four mifepristone concentrations (0.

View Article and Find Full Text PDF

Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin.

Cancer Cell Int

November 2018

1Experimental Pathology Unit, Department of Pathology, Faculty of Medicine, McGill University, 3775 University Street, Montreal, QC H3A 2B4 Canada.

Background: Lung cancer is the leading cause of cancer deaths in the world. The major histopathological subtype of lung cancer is non-small cell lung cancer (NSCLC). Platinum-based therapy is the standard of care for patients with advanced stage NSCLC.

View Article and Find Full Text PDF

Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.

Horm Cancer

April 2016

Service de Gynécologie Obstétrique Médecine de la Reproduction, Hôpitaux Universitaires Est Parisien site Tenon, Assistance Publique-Hôpitaux de Paris, 4 Rue de la Chine, 75020, Paris, France.

Breast cancer is a hormone-dependent disease in which estrogen signaling targeting drugs fail in about 10 % due to resistance. Strong evidences highlighted the mitogen role of progesterone, its ligands, and the corresponding progesterone receptor (PR) isoforms in mammary carcinoma. Several PR antagonists have been synthesized; however, some of them are non-selective and led to side or toxic effects.

View Article and Find Full Text PDF

Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study.

BMC Cancer

January 2015

Instituto Nacional de Cancerología, Subdirección de Investigación Básica, México D.F., 14080, México.

Background: Over the past few years, the concurrent use of cisplatin-based chemotherapy and radiation therapy has dramatically improved the local response and increased overall survival in early-stage cervical cancer. However, for the advanced stages of the disease this standard treatment has proved insufficient. We investigated the capacity of Mifepristone and ICI 182,780, which are anti-progestin and anti-estrogen drugs, respectively, to act as chemo-radiosensitizing agents in cervical cancer cells and cervix xenografts.

View Article and Find Full Text PDF

Pre-clinical and clinical studies have employed treatment with glucocorticoid receptor (GR) antagonists in an attempt to limit the deleterious behavioral and physiological effects of excess glucocorticoids. Here, we examined the effects of GR antagonists on neuroendocrine and behavioral stress responses, using two compounds: mifepristone, a GR antagonist that is also a progesterone receptor antagonist, and CORT 108297, a specific GR antagonist lacking anti-progestin activity. Given its well-documented impact on neuroendocrine and behavioral stress responses, imipramine (tricyclic antidepressant) served as a positive control.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!